228 related articles for article (PubMed ID: 32164461)
21. Palbociclib: A new hope in the treatment of breast cancer.
Palanisamy RP
J Cancer Res Ther; 2016; 12(4):1220-1223. PubMed ID: 28169231
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma.
Ramakrishnan VG; Kumar SK
Cancer J; 2016; 22(1):7-11. PubMed ID: 26841010
[TBL] [Abstract][Full Text] [Related]
23. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.
Mita M; Gordon M; Rosen L; Kapoor N; Choy G; Redkar S; Taverna P; Oganesian A; Sahai A; Azab M; Bristow R; Tolcher AW
Cancer Chemother Pharmacol; 2014 Jul; 74(1):195-204. PubMed ID: 24849582
[TBL] [Abstract][Full Text] [Related]
24. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.
Bury M; Le Calvé B; Ferbeyre G; Blank V; Lessard F
Trends Cell Biol; 2021 May; 31(5):331-344. PubMed ID: 33676803
[TBL] [Abstract][Full Text] [Related]
25. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
26. Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Giannone G; Tuninetti V; Ghisoni E; Genta S; Scotto G; Mittica G; Valabrega G
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31083638
[TBL] [Abstract][Full Text] [Related]
27. Cell cycle inhibitors for the treatment of NSCLC.
Shcherba M; Liang Y; Fernandes D; Perez-Soler R; Cheng H
Expert Opin Pharmacother; 2014 May; 15(7):991-1004. PubMed ID: 24666387
[TBL] [Abstract][Full Text] [Related]
28. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Aug; 15(12):1771-80. PubMed ID: 25032887
[TBL] [Abstract][Full Text] [Related]
30. Brigatinib effective in ALK-positive non-small-cell lung cancer.
Das M
Lancet Oncol; 2017 Jun; 18(6):e310. PubMed ID: 28506557
[No Abstract] [Full Text] [Related]
31. Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
Indini A; Rijavec E; Ghidini M; Bareggi C; Gambini D; Galassi B; Antonelli P; Bettio G; Di Nubila C; Grossi F
Expert Opin Pharmacother; 2020 Jun; 21(8):931-940. PubMed ID: 32162559
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
33. Anticancer therapeutic strategies based on CDK inhibitors.
Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
[TBL] [Abstract][Full Text] [Related]
34. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Jhaveri K; Burris Rd HA; Yap TA; Hamilton E; Rugo HS; Goldman JW; Dann S; Liu F; Wong GY; Krupka H; Shapiro GI
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1105-1124. PubMed ID: 34176404
[No Abstract] [Full Text] [Related]
35. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
36. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
37. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
39. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
Bruyère C; Meijer L
Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
[TBL] [Abstract][Full Text] [Related]
40. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]